TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
0.9962
-0.0138 (-1.37%)
Apr 21, 2025, 4:00 PM EDT - Market closed

TherapeuticsMD Statistics

Total Valuation

TherapeuticsMD has a market cap or net worth of $11.53 million. The enterprise value is $13.65 million.

Market Cap 11.53M
Enterprise Value 13.65M

Important Dates

The next estimated earnings date is Friday, May 9, 2025, after market close.

Earnings Date May 9, 2025
Ex-Dividend Date n/a

Share Statistics

TherapeuticsMD has 11.57 million shares outstanding. The number of shares has increased by 10.45% in one year.

Current Share Class 11.57M
Shares Outstanding 11.57M
Shares Change (YoY) +10.45%
Shares Change (QoQ) n/a
Owned by Insiders (%) 2.02%
Owned by Institutions (%) 14.71%
Float 9.51M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 6.52
Forward PS n/a
PB Ratio 0.42
P/TBV Ratio 0.50
P/FCF Ratio 15.75
P/OCF Ratio 15.75
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 7.75
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF 18.64

Financial Position

The company has a current ratio of 2.37, with a Debt / Equity ratio of 0.26.

Current Ratio 2.37
Quick Ratio 1.67
Debt / Equity 0.26
Debt / EBITDA n/a
Debt / FCF 9.80
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -8.16% and return on invested capital (ROIC) is -6.08%.

Return on Equity (ROE) -8.16%
Return on Assets (ROA) -5.31%
Return on Invested Capital (ROIC) -6.08%
Return on Capital Employed (ROCE) -10.38%
Revenue Per Employee $1.76M
Profits Per Employee -$2.18M
Employee Count 1
Asset Turnover 0.04
Inventory Turnover n/a

Taxes

Income Tax -31,000
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -46.44% in the last 52 weeks. The beta is 0.95, so TherapeuticsMD's price volatility has been similar to the market average.

Beta (5Y) 0.95
52-Week Price Change -46.44%
50-Day Moving Average 0.93
200-Day Moving Average 1.36
Relative Strength Index (RSI) 54.82
Average Volume (20 Days) 42,959

Short Selling Information

The latest short interest is 169,192, so 1.46% of the outstanding shares have been sold short.

Short Interest 169,192
Short Previous Month 170,162
Short % of Shares Out 1.46%
Short % of Float 1.78%
Short Ratio (days to cover) 2.31

Income Statement

In the last 12 months, TherapeuticsMD had revenue of $1.76 million and -$2.18 million in losses. Loss per share was -$0.19.

Revenue 1.76M
Gross Profit 1.76M
Operating Income -3.49M
Pretax Income -6.13M
Net Income -2.18M
EBITDA -2.98M
EBIT -3.49M
Loss Per Share -$0.19
Full Income Statement

Balance Sheet

The company has $5.06 million in cash and $7.18 million in debt, giving a net cash position of -$2.12 million or -$0.18 per share.

Cash & Cash Equivalents 5.06M
Total Debt 7.18M
Net Cash -2.12M
Net Cash Per Share -$0.18
Equity (Book Value) 27.37M
Book Value Per Share 2.37
Working Capital 7.09M
Full Balance Sheet

Cash Flow

Operating Cash Flow 732,000
Capital Expenditures n/a
Free Cash Flow 732,000
FCF Per Share $0.06
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -198.30% and -123.85%.

Gross Margin 100.00%
Operating Margin -198.30%
Pretax Margin -133.05%
Profit Margin -123.85%
EBITDA Margin -169.39%
EBIT Margin -198.30%
FCF Margin 41.57%

Dividends & Yields

TherapeuticsMD does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -10.45%
Shareholder Yield -10.45%
Earnings Yield -18.92%
FCF Yield 6.35%
Dividend Details

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on May 9, 2022. It was a reverse split with a ratio of 0.02:1.

Last Split Date May 9, 2022
Split Type Reverse
Split Ratio 0.02:1

Scores

TherapeuticsMD has an Altman Z-Score of -33.23 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -33.23
Piotroski F-Score 4